The surge in U.S. oil production since 2008 has created tremendous opportunities for the midstream companies involved in oil storage and transportation. Many continue to invest record amounts of cash into new projects to help alleviate regional supply bottlenecks and get the crude oil to those who demand it.
But despite midstream companies' best efforts, they've lost a great deal of market share to railroads, which have rapidly emerged as their biggest competitors over the past couple of years. Let's take a look at how railroads have turned the logistics of crude oil transport on its head and what the future may hold for crude-by-rail.
The staggering growth of crude by rail
Today, the rail industry is transporting more oil than it has since the days of John D. Rockefeller's Standard Oil. In the first quarter of 2013, railways shipped a record 97,135 carloads of crude oil, according to the Association of American Railroads. That represents a 166% increase over the first quarter of 2012 and a 922% gain over crude rail shipments during the entirety of 2008.
Top 10 Construction Stocks To Watch Right Now: Richoux Group PLC (RIC)
Richoux Group plc is a United Kingdom-based company engaged in the operation of restaurants. The Company has three segments: Richoux, Villagio Zippers and Dean�� Diner. Richoux restaurants operate in the areas of central London. The restaurants are open all day for breakfast, lunch, afternoon tea and dinner. The restaurants also offers patisserie. Zippers is a spacious, stylish and contemporary restaurant with a relaxed ambience. Dean's Diner offers a range of freshly prepared dishes. Villagio is a modern local Italian restaurant with a menu suitable for the whole family. The Company�� subsidiaries include Newultra Limited and Richoux Limited. Advisors' Opinion:- [By Sally Jones]
Richmont Mines Inc. (RIC)Down 70% over 12 months, Richmont Mines Inc. has a market cap of $56.23 billion, and trades with a P/B of 0.60.
- [By Roberto Pedone]
Richmont Mines (RIC) engages in the mining, exploration and development of mining properties, principally gold in Canada. This stock closed up 2.4% to $1.68 in Tuesday's trading session.
Tuesday's Range: $1.61-$1.68
52-Week Range: $1.31-$5.50
Tuesday's Volume: 76,000
Three-Month Average Volume: 101,786From a technical perspective, RIC bounced higher here right off its 50-day moving average of $1.59 with decent upside volume. This stock has been uptrending strong for the last month and change, with shares moving higher from its low of $1.31 to its recent high of $1.71. During that move, shares of RIC have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of RIC within range of triggering a near-term breakout trade. That trade will hit if RIC manages to take out some near-term overhead resistance at $1.71 to $1.80 with high volume.
Traders should now look for long-biased trades in RIC as long as it's trending above its 50-day at $1.59 or above more near-term support levels at $1.50 to $1.44 and then once it sustains a move or close above those breakout levels with volume that hits near or above 101,786 shares. If that breakout triggers soon, then RIC will set up to re-test or possibly take out its next major overhead resistance levels at $2.10 to $2.20. Any high-volume move above those levels will then give RIC a chance to tag its 200-day moving average at $2.48.
Top Logistics Stocks To Invest In Right Now: Elan Corporation PLC (ELN)
Elan Corporation, plc (Elan), incorporated in December 1969, is a neuroscience-based biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. Elan�� business focuses on neurodegenerative diseases, such as Alzheimer�� disease and Parkinson�� disease; autoimmune diseases, including MS and Crohn�� disease and neo-epitope based targets for treatments across a range of therapeutic indications. Tysabri is a treatment for MS and Crohn�� disease that the Company markets and distributes with Biogen Idec. On September 16, 2011, Elan sold its EDT business to Alkermes, Inc. In November 2011, Elan launched a collaboration with the University of Cambridge, England, the Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre). On December 21, 2012, the Company completed the demerger of Prothena Corporation plc. In April 2013, it closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.
Tysabri
Tysabri, which is an alpha-4 integrin inhibitor, is a therapy for MS, a neurological disorder involving central nervous system dysfunction among adults. Tysabri is approved in more than 65 countries. Tysabri is approved in the United States as a monotherapy for relapsing forms of MS, for patients who have had an inadequate response to, or are unable to tolerate, an alternative MS therapy. In the European Union, it is approved for relapsing-remitting MS (RRMS) in adult patients who have failed to respond to beta interferon or have rapidly evolving, severe RRMS. As of December 31, 2011, there were approximately 64,400 patients on Tysabri therapy worldwide.
In June 2011, the European Commission (EC) approved the inclusion of the anti-JCV antibody status as an additional factor in stratifying patients at risk for developing PML in the Summary of Product Characteristics��(SmPC) for Tysabri in the European Union. The Company has developed a two-step ! enzyme-linked immunosorbent assay (ELISA), STRATIFY JCV, with Biogen Idec. The assay detects anti-JCV antibodies in the blood of patients, and is commercially available in Europe. In January 2012, the FDA cleared the assay for commercial use in the United States. As of December 31, 2011, over 80,000 tests had been administered using the assay. Tysabri is marketed and distributed by Elan and Biogen Idec. The Company�� research group, Neotope, is focused on creating monoclonal antibodies based on neo-epitope targets for the treatment of a range of therapeutic indications.
Beta Amyloid Immunotherapies (AIP)
Beta amyloid immunotherapy includes the treatment of Alzheimer�� disease by inducing or enhancing the body�� immune response in order to clear toxic species of beta amyloid from the brain. The AIP includes bapineuzumab (intravenous and subcutaneous delivery) and ACC-001, as well as other compounds. Bapineuzumab is an experimental humanized monoclonal antibody delivered intravenously that is being studied as a treatment for mild to moderate Alzheimer�� disease. It is designed to provide antibodies to beta amyloid directly to the patient (passive immunotherapy).
ELND005, an A� Aggregation Inhibitor
The small molecule ELND005 (Scyllo-inositol) is a beta amyloid anti-aggregation agent. Preclinical data suggest that ELND005 may act through the mechanism of preventing and reversing the fibrilisation of beta amyloid (the aggregation of beta amyloid into clumps of insoluble oligomers). ELND005 may have additional applications in psychiatric indications, such as bipolar disorder. In November 2011, the Company entered into a manufacturing agreement for the supply of the active pharmaceutical ingredient for ELND005 with Lonza Group AG.
Neotope Biosciences Limited
Neotope Biosciences Limited (Neotope) is the Company�� wholly owned subsidiary that focuses on the discovery and development of antibodies to neo-epitope related targ! ets for t! he treatment of a range of indications. It includes amyloidosis, diabetes, cancer and macular degeneration. Neotope�� portfolio of targets includes alpha-synuclein for the potential treatment of synucleinopathies, such as Lewy body dementia and Parkinson�� disease, tau for Alzheimer�� disease and other tauopathies. It also has a program for type 2-diabetes.
Onclave Therapeutics Limited
Elan�� wholly owned subsidiary Onclave Therapeutics Limited (Onclave) was formed to develop assets originating from Elan that have application in oncology related diseases. Onclave�� program, NEOD001, which originated from Neotope, is being investigated for the treatment of AL amyloidosis, which is a fatal disease involving abnormal accumulation of amyloid in organs and tissue. During the year ended December 31, 2011, Onclave filed for orphan drug designation of NEOD001. Onclave�� pipeline includes additional compounds with relevance in diverse cancer indications.
The Company competes with Biogen Idec, Bayer Schering Pharma AG, Bayer Schering Pharma, Merck Serono, Pfizer, Teva Neurosciences, Inc., Sanofi-Aventis and Novartis AG.
Advisors' Opinion:- [By Russ Krull]
Finally, Ireland-based biotech Elan (NYSE: ELN ) issued $850 million of eight-year notes. The money is going to help pay for a royalty stake in some Theravance products. Elan expects the transaction to add to earnings starting in 2014. My Foolish colleagues Sean Williams and Brian Orelli think this might be a better deal for Theravance than for Elan.
- [By Brian Orelli]
Royalty Pharma announced Monday that it's willing increase the $11-per-share offer it made for Elan (NYSE: ELN ) back in February, depending on the result of Elan's buyback.
Top Logistics Stocks To Invest In Right Now: Werner Enterprises Inc (WERN)
Werner Enterprises, Inc., incorporated on September 14, 1982, is a transportation and logistics company engaged primarily in hauling truckload shipments of general commodities in both interstate and intrastate commerce. The Company also provides logistics services through its value added services (VAS) division. As of the year ended December 31, 2012, the Company had a fleet of 7,150 trucks, of which 6,505 were Company-operated and 645 were owned and operated by independent contractors. The Company operates in two segments: Truckload Transportation Services (Truckload) and VAS.
Truckload segment
The Company's Truckload segment consists of the One-Way Truckload and Specialized Services units. One-Way Truckload includes the operating fleets: the regional short-haul (Regional) fleet transports a variety of consumer nondurable products and other commodities in truckload quantities within geographic regions across the United States using dry van trailers; the medium-to-long-haul van (Van) fleet provides comparable truckload van service over irregular routes, and the expedited (Expedited) fleet provides time-sensitive truckload services utilizing driver teams.
Specialized Services provides truckload services dedicated to a specific customer, generally for a retail distribution center or manufacturing facility, including services for products requiring specialized trailers such as flatbed or temperature-controlled trailers. The Company's Truckload fleets operate throughout the 48 contiguous United States, both common and contract, granted by the United States Department of Transportation (DOT). The Company also has authority to operate in several provinces of Canada and to provide through-trailer service into and out of Mexico. The principal types of freight the Company transports include retail store merchandise, consumer products, grocery products and manufactured products. The Company focuses on transporting consumer nondurable products that generally ship.
!
VAS segment
The Company's VAS segment is a non-asset-based transportation and logistics provider. VAS is consists of four operating units that provide non-trucking services to the Company's customers: truck brokerage (Brokerage) uses contracted carriers to complete customer shipments; freight management (Freight Management) offers a range of single-source logistics management services and solutions; the intermodal (Intermodal) unit offers rail transportation through alliances with rail and drayage providers as an alternative to truck transportation, and Werner Global Logistics international (WGL) provides complete management of global shipments from origin to destination using a combination of air, ocean, truck and rail transportation modes. The Company's Brokerage unit had transportation services contracts with approximately 9,400 carriers as of December 31, 2012.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading DOWN
Shares of Outerwall (NASDAQ: OUTR) were down 16.03 percent to $47.00 after the company lowered its forecast for the third quarter and full year. Werner Enterprises (NASDAQ: WERN) shares tumbled 4.71 percent to $23.26 after the company issued a weak third-quarter profit forecast. Bank of America downgraded the stock from Buy to Neutral. Pandora Media (NYSE: P) down, falling 1.71 percent to $23.58 as the company announced its plans to sell 14 million shares of common stock, including 4 million shares from current stockholders. - [By Seth Jayson]
Werner Enterprises (Nasdaq: WERN ) reported earnings on April 18. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Werner Enterprises missed estimates on revenues and missed estimates on earnings per share. - [By Mike Deane]
Werner Enterprises (WERN) announced its third quarter earnings after the bell on Thursday, posting a 1% change in revenues from last year’s Q3, but a 15% drop in net income.
The Omaha, NE-based logistics and transportation company announced Q3 revenue of $511.73 million, which was up slightly from last year’s $506.50 million revenue figure. WERN reported net income for the quarter of $21.53 million, or 29 cents per diluted share, which was down from last year’s Q3 earnings of $25.13 million, or 34 cents per diluted share.
The company was able to meet analyst views of 29 cents EPS, and slightly surpass the revenue estimate of $503.82 million.
WERN shares were up 21 cents, or 0.90%, at Thursday’s market close, but were edging lower in after-hours trading. YTD, the company’s stock is up just over 4%.
- [By Monica Gerson]
Werner Enterprises (NASDAQ: WERN) is expected to post its Q3 earnings at $0.29 per share on revenue of $503.82 million.
Chipotle Mexican Grill (NYSE: CMG) is estimated to post its Q3 earnings at $2.78 per share on revenue of $820.28 million.
Top Logistics Stocks To Invest In Right Now: Clayton Williams Energy Inc (CWEI)
Clayton Williams Energy, Inc. (CWEI), incorporated on December 27, 1991, is an independent oil and gas company engaged in the exploration for and production of oil and natural gas primarily in Texas, Louisiana and New Mexico. The Company operates in two segments: oil and gas exploration and production and contract drilling services. As of December 31, 2012, its portfolio of oil and natural gas reserves is weighted in favor of oil, with approximately 77% of its proved reserves consisting of oil and natural gas liquids (NGLs) and approximately 23% consisting of natural gas. During the year ended December 31, 2012, the Company added proved reserves of 20,443 million barrels of oil equivalent (MBOE) through extensions and discoveries, had downward revisions of 6,615 MBOE and had purchases of minerals-in-place of 3,504 MBOE and had a sales of minerals-in-place of 725 MBOE. As of December 31, 2012, CWEI held interests in 3,031 gross (1749 net) producing oil and gas wells and owned leasehold interests in approximately 951,000 gross (471,000 net) undeveloped acres. On March 14, 2012, its wholly owned subsidiary, Southwest Royalties, Inc. (SWR), completed the mergers of each of the 24 limited partnerships, of which SWR is the general partner (SWR Partnerships) into SWR.
Permian Basin
The Company�� Permian Basin is a sedimentary basin in West Texas and Southeastern New Mexico. The Permian Basin covers an area approximately 250 miles wide and 350 miles long and contains commercial accumulations of oil and gas in multiple stratigraphic horizons at depths ranging from 1,000 feet to over 25,000 feet. During 2012, the Company drilled and completed 87 gross (80.2 net) operated wells in the Permian Basin and conducted various remedial operations on other wells. As of December 31, 2012, the Company had two rigs in this area.
Giddings Area
The Company�� Austin Chalk formation is an upper Cretaceous geologic formation in the Gulf Coast region of the United States th! at stretches across numerous fields in Texas and Louisiana. The Austin Chalk formation is generally encountered at depths of 5,500 to 7,000 feet. Horizontal drilling is the primary technique used in the Austin Chalk formation. Its wells in this area were drilled as horizontal wells, many with multiple laterals in different producing horizons, including the Austin Chalk, Buda and Georgetown formations in East Central Texas. The Eagle Ford Shale formation lies immediately beneath the Austin Chalk formation where the Company have approximately 177,000 net acres in production. As of December 31, 2012, the Company is using one of its drilling rigs in the Giddings Area to drill horizontal wells in the Eagle Ford Shale formation.
South Louisiana
During 2012, the Company drilled and completed the Hassinger ETAL #1, an exploratory well in Jefferson Parish, Louisiana. The Company plan to commence drilling operations on the Macon Stringer Heirs #1, an exploratory well in Terrebonne Parish in 2013.
Natural Gas Services
The Company owns an interest in and operates natural gas service facilities in the states of Texas and Louisiana. These natural gas service facilities consist of interests in approximately 314 miles of pipeline, three treating plants, one dehydration facility, and seven wellhead type treating and/or compression stations. Its operated gas gathering and treating activities exist to facilitate the transportation and marketing of its operated oil and gas production.
Advisors' Opinion:- [By Seth Jayson]
Clayton Williams Energy (Nasdaq: CWEI ) is expected to report Q1 earnings around April 24. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Clayton Williams Energy's revenues will decrease -8.9% and EPS will shrink -32.8%.
Top Logistics Stocks To Invest In Right Now: InSite Vision Inc (INSV)
InSite Vision Incorporated (InSite), incorporated in 1986, is an ophthalmic product development company advancing ophthalmic pharmaceutical products to address unmet eye care needs. The Company's current portfolio of products is based on the Company's DuraSite sustained drug delivery technology. Its DuraSite sustained drug delivery technology is a synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a drug as a solution, gel or suspension and can be customized for delivering a wide variety of drug candidates. The Company is focused its research and development and commercial support efforts on the topical products formulated with its DuraSite drug delivery technology. It may also utilize its DuraSite technology platform for the formulation of new ocular product candidates using either non drugs or compounds developed by others for non-ophthalmic indications.
AzaSite (azithromycin ophthalmic solution) 1% is a DuraSite formulation of azithromycin developed as a spectrum ocular antibiotic and approved by the United States Food and Drug Administration (FDA) to treat bacterial conjunctivitis (pink eye). Azithromycin has a spectrum of antibiotic activity and is used to treat respiratory and other infections in its oral and parenteral forms.
Besivance (besifloxacin ophthalmic suspension) 0.6% is a DuraSite formulation of besifloxacin, a spectrum ocular antibiotic approved by the FDA to treat bacterial conjunctivitis (pink eye). Besivance is the fluoroquinolone specifically developed for ophthalmic use. AzaSite Plus (ISV-502) is a fixed combination of azithromycin and dexamethasone in DuraSite for the treatment of ocular inflammation and infection (blepharitis and/or blepharoconjunctivitis).
DexaSite (ISV-305) is a DuraSite formulation of dexamethasone in development for the treatment of ocular inflammation. DexaSite is included in the Phase 3 clinical trial SPA for ! AzaSite Plus. The Company developed a topical formulation of the corticosteroid dexamethasone to treat eye inflammation caused by infections, injury, surgery or other conditions.
BromSite (ISV-303) is a DuraSite formulation of bromfenac in development for the treatment of post-operative inflammation and eye pain. ISV-101 is a DuraSite formulation with a low concentration of bromfenac for the treatment of dry eye disease.
The Company competes with Alcon Laboratories, Inc., Allergan, Inc., Bausch & Lomb, Novartis Ophthalmics, Johnson & Johnson, Merck & Co. and Pfizer.
Advisors' Opinion:- [By CRWE]
Today, INSV surged (+7.53%) up +0.014 at $.200 with 96,500 shares in play thus far (ref. google finance Delayed: 1:12PM EDT August 15, 2013).
InSite Vision Incorporated previously reported financial results for the quarter ended June 30, 2013. Revenues for the second quarter of 2013 were $19.2 million compared to $1.8 million for the same period in 2012. Included in the second quarter of 2013 were revenues of $15 million for the sale of the Besivance庐 royalty rights. Net income for the second quarter of 2013 was $12.1 million, or $0.09 per share, compared to a net loss of $6.8 million, or $0.05 per share, in the second quarter of 2012.
No comments:
Post a Comment